Literature DB >> 24665929

Androgenetic alopecia and polymorphism of the androgen receptor gene (SNP rs6152) in patients with benign prostate hyperplasia or prostate cancer.

R Kucerova1, M Bienova, M Kral, J Bouchal, K S Trtkova, A Burdova, V Student, Z Kolar.   

Abstract

BACKGROUND: Both androgenetic alopecia (AGA) and carcinoma of the prostate (CaP) or benign prostatic hyperplasia (BPH) are androgen-dependent disorders.
OBJECTIVE: To investigate the relationships between male androgenetic alopecia, androgen receptor (AR) gene polymorphism (SNP rs6152) and clinical characteristics of BPH and prostate cancer.
METHODS: Overall, 309 male subjects with prostate disease (BPH or CaP) were examined. We evaluated the standard grades of AGA (I-VII) by Hamilton-Norwood classification and 195 patients were also assessed by phototrichogram. Prostate-specific antigen (PSA) and testosterone levels were also measured. Polymorphism rs6152 of the AR was evaluated from blood samples by PCR-RFLP. Data were statistically evaluated.
RESULTS: The expected positive correlation between age and AGA grade and the expected negative correlation between hair density and age and between anagen/telogen and AGA were found. A statistically significant difference between patients with A and G alleles in terms of AGA grade was found. The predominant G allele was more frequent in patients with higher grade of alopecia and in patients with significantly higher PSA. There was no correlation between diagnosis (BPH or CaP) and polymorphism. Patients with prostate inflammation had a statistically significant higher grade of AGA, together with higher PSA.
CONCLUSIONS: We confirmed that the AR gene polymorphism (SNP rs6152 G>A) is associated with the development of AGA and higher PSA levels in patients with BPH but not cancer. A novel finding of our study is that BPH patients with prostate inflammation had a significantly higher grade of AGA together with significantly higher PSA levels.
© 2014 European Academy of Dermatology and Venereology.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24665929     DOI: 10.1111/jdv.12468

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN: 0926-9959            Impact factor:   6.166


  7 in total

Review 1.  Does a male polycystic ovarian syndrome equivalent exist?

Authors:  R Cannarella; R A Condorelli; L M Mongioì; S La Vignera; A E Calogero
Journal:  J Endocrinol Invest       Date:  2017-07-15       Impact factor: 4.256

2.  Baldness and Risk of Prostate Cancer in the Health Professionals Follow-up Study.

Authors:  Saud Khan; Joshua Caldwell; Travis A Gerke; Sarah C Markt; Kathryn M Wilson; Amparo G Gonzalez-Feliciano; Samuel Peisch; Claire H Pernar; Rebecca E Graff; Edward L Giovannucci; Lorelei A Mucci
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2020-04-10       Impact factor: 4.254

Review 3.  Genetic association between PSA-158G/A polymorphism and the susceptibility of benign prostatic hyperplasia: a meta-analysis.

Authors:  Xin-Jun Su; Xian-Tao Zeng; Cheng Fang; Tong-Zu Liu; Xing-Huan Wang
Journal:  Oncotarget       Date:  2017-05-16

Review 4.  Comorbidities in Androgenetic Alopecia: A Comprehensive Review.

Authors:  Shuang Chen; Xiaohang Xie; Guoqiong Zhang; Yong Zhang
Journal:  Dermatol Ther (Heidelb)       Date:  2022-09-17

5.  Association of premature androgenetic alopecia and metabolic syndrome in a young Indian population.

Authors:  S Chakrabarty; R Hariharan; Dg Gowda; Hemalini Suresh
Journal:  Int J Trichology       Date:  2014-04

6.  Are 2D:4D finger-length ratios an indicator of androgenetic alopecia in males?

Authors:  Özlem Bilgic; Hilmi Cevdet Altınyazar; Dilek Eryılmaz; Zehra Ayça Tuğrul
Journal:  An Bras Dermatol       Date:  2016-04       Impact factor: 1.896

Review 7.  Endocrinology of the Aging Prostate: Current Concepts.

Authors:  Rossella Cannarella; Rosita A Condorelli; Federica Barbagallo; Sandro La Vignera; Aldo E Calogero
Journal:  Front Endocrinol (Lausanne)       Date:  2021-02-22       Impact factor: 5.555

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.